MENLO PARK, Calif., July 11 /PRNewswire/ -- ROXRO PHARMA, Inc. has appointed Gayle Mills, former Senior Vice President of Business Development at Abgenix, Inc. to the new position of Executive Vice President, Business Operations. Ms. Mills brings more than 20 years of healthcare experience to the role. She will focus on leading the strategy, business development and marketing activities for the company’s portfolio of new medicines to treat pain.
“Gayle is one of the most successful business development executives in the biotechnology industry, forging profitable relationships with many major biotechnology and pharmaceutical companies,” said Roberto Rosenkranz, Ph.D., Chairman and Chief Executive Officer of ROXRO PHARMA. “That experience along with her background in pharmaceutical sales and marketing will be extremely valuable to ROXRO particularly as we near the market with our lead compound.”
Mills led the business development activities of Abgenix, Inc. from 2000 to 2006. Previously she was Vice President, Business Development at Eos Biotechnology, Inc. (subsequently purchased by Protein Design Labs) and Vice President, Strategic Marketing and Business Development for the Neurobiology Unit of Roche Bioscience. Her early career includes senior business development and marketing management positions at Affymax N.V., Syntex Corporation and Monoclonal Antibodies/Quidel Corporation.
Mill is a past co-chair of the Biotechnology Industry Organization (BIO) business development committee. During her tenure, she played a pivotal role in the creation of a highly successful annual conference for partnering in the U.S.
Mills holds an MBA from Santa Clara University.
About ROXRO PHARMA, Inc.
ROXRO PHARMA, Inc. is a privately-owned specialty pharmaceutical company focused on the treatment of pain. Founded in 1999, ROXRO in-licenses promising drug candidates for rapid development in acute medical conditions. The company’s highly experienced staff engages a global network of external experts to conduct preclinical and clinical studies and to manufacture drug products. ROXRO’s lead compound, ROX-888 is currently in Phase III trials for the indication of post-operative pain. The company’s earlier pipeline includes a Phase II compound for headache and a preclinical compound for neuropathic pain.
ROXRO PHARMA, Inc.
CONTACT: Roberto Rosenkranz or Roger Whiting for ROXRO PHARMA, Inc.,+1-650-322-4554
